Generic Name and Formulations:
Alglucosidase alfa 5mg/mL; pwd for IV infusion after reconstitution and dilution; preservative-free.
Sanofi Genzyme Company
Indications for MYOZYME:
Pompe disease (GAA deficiency).
Give by IV infusion over 4 hours. Initial infusion rate: 1mg/kg/hr, may increase to 2mg/kg/hr every 30 minutes after tolerance established to max 7mg/kg/hr. 20mg/kg every 2 weeks.
Discontinue immediately if severe anaphylactic or allergic reactions develop; have appropriate medical support measures available and during rechallenge. Increased risk of acute cardiorespiratory failure with acute underlying respiratory illness, compromised cardiac function, or sepsis. Cardiac hypertrophy (increased risk of cardiac arrhythmia when given general anesthesia for central venous catheter placement). Infants with cardiac dysfunction may require prolonged observation times. Monitor for development of systemic immune complex-mediated reactions; consider discontinuing if occurs. Monitor for IgG antibody formation every 3 months for 2 years, then annually. Perform LFTs prior to initiation; monitor periodically. Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
Recombinant human alpha-glucosidase enzyme.
Pneumonia, respiratory failure/distress, catheter-related infection, respiratory syncytial virus infection, gastroenteritis, fever; infusion reactions (temporarily stop or reduce infusion rate; discontinue if severe).
Single-use vial (50mg)—1
Endocrinology Advisor Articles
- Effect of HbA1c and Perioperative Glucose on Postoperative Mortality
- GLP-1 Agonists Superior to DPP-4 Inhibitors for Reducing HbA1c, Weight in T2D
- Semaglutide May Be Useful for Treating Obesity in People Without Diabetes
- Effect of Growth Hormone Treatment on BMD in Adults With Prader-Willi Syndrome
- Once-Daily Oral Contraceptive for Men Shows Promise
- American College of Physicians Releases 4 Guidelines for HbA1c Targets in T2D
- Dyslipidemia Drug Indications
- No Difference in Weight Loss Outcomes With Low-Fat vs Low-Carbohydrate Diet
- Damaging Effects of Gastric Bypass Surgery on Bone Mass and Microarchitecture
- Gastric Bypass Surgery Linked to Increased Risk for Nonvertebral Fractures
- Metformin May Improve Pregnancy Outcomes in Polycystic Ovary Syndrome
- HbA1c Levels Affect Serum Phospholipids, Inflammation inT2D, CVD
- No Cardiovascular Benefit With Fenofibrate in T2D and Hypertriglyceridemia
- Cardiovascular Function May Improve After Cure of Cushing Syndrome
- Primary Prevention Outcomes With Aspirin in T2D and Heart Failure